SiteBridge Research Announces Bridging the Gap for Clinical Trials Art Contest
Using the potential of art to stimulate important conversations, the Bridging the Gap for Clinical Trials Art Contest will bind multiple levels of influence—individual, social/cultural, organizational, community, and public policy to advance diversity in clinical trials.
Clinical trial professionals can get involved through the following options:
- Becoming a sponsor or collaborator—community engagement (which is different from patient recruitment, patient engagement, and patient communities) is a relatively new concept in the clinical trial space. This contest offers the opportunity to collaborate with/sponsor an event designed to promote diversity in clinical trials and create awareness and understanding about clinical trial participation. Clinical trial participants are at the center of the industry. Without the participants, there would be no clinical trials, and therefore, no trialist profession.
- Spreading the news on social media.
- Participating—clinical trial professionals who also have an artistic side are welcome to enter any of the three categories, as long as they have no conflict of interest as outlined in the contest rules.
For more information on entry, sponsorship opportunities, categories, and rules, visit the contest's homepage here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
